Nicholas E Johnson1, Diana Abbott2, Lisa A Cannon-Albright2,3. 1. Department of Neurology, University of Utah School of Medicine, Salt Lake City, 30 N 1900 SOM 3E228, Utah, 84132, USA. 2. Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA. 3. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, USA.
Abstract
INTRODUCTION: A population-level relative risk assessment for comorbidities associated with myotonic dystrophy has not been performed. METHODS: In this study we utilized the Utah Population Database to identify patients with myotonic dystrophy in Utah according to ICD-9 coding. Comorbidity cases listed in the medical record were compared with those of the Utah population. RESULTS: Individuals with myotonic dystrophy were found to possess an increased risk of central and obstructive sleep apnea, hypothyroidism, and intellectual disability. The risk of cardiac conduction disorder is 60 times the population risk. CONCLUSIONS: This study provides a population-level relative risk assessment of comorbidities in myotonic dystrophy. This allows for improved counseling of patients regarding these increased risks.
INTRODUCTION: A population-level relative risk assessment for comorbidities associated with myotonic dystrophy has not been performed. METHODS: In this study we utilized the Utah Population Database to identify patients with myotonic dystrophy in Utah according to ICD-9 coding. Comorbidity cases listed in the medical record were compared with those of the Utah population. RESULTS: Individuals with myotonic dystrophy were found to possess an increased risk of central and obstructive sleep apnea, hypothyroidism, and intellectual disability. The risk of cardiac conduction disorder is 60 times the population risk. CONCLUSIONS: This study provides a population-level relative risk assessment of comorbidities in myotonic dystrophy. This allows for improved counseling of patients regarding these increased risks.
Authors: Linda L Bachinski; Bjarne Udd; Giovanni Meola; Valeria Sansone; Guillaume Bassez; Bruno Eymard; Charles A Thornton; Richard T Moxley; Peter S Harper; Mark T Rogers; Karin Jurkat-Rott; Frank Lehmann-Horn; Thomas Wieser; Josep Gamez; Carmen Navarro; Armand Bottani; Andre Kohler; Mark D Shriver; Riitta Sallinen; Maija Wessman; Shanxiang Zhang; Fred A Wright; Ralf Krahe Journal: Am J Hum Genet Date: 2003-09-10 Impact factor: 11.025
Authors: J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson Journal: Cell Date: 1992-02-21 Impact factor: 41.582
Authors: Tiina Suominen; Linda L Bachinski; Satu Auvinen; Peter Hackman; Keith A Baggerly; Corrado Angelini; Leena Peltonen; Ralf Krahe; Bjarne Udd Journal: Eur J Hum Genet Date: 2011-03-02 Impact factor: 4.246
Authors: Ian S Mutchnick; Meena A Thatikunta; William C Gump; Dan L Stewart; Thomas M Moriarty Journal: Childs Nerv Syst Date: 2016-01-08 Impact factor: 1.475
Authors: Sarah J Howe; David Lapidus; Michael Hull; Jason Yeaw; Tanya Stevenson; Jacinda B Sampson Journal: Orphanet J Rare Dis Date: 2022-02-23 Impact factor: 4.303